MEDIPOST Co. Ltd (078160) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MEDIPOST Co. Ltd (078160) has a cash flow conversion efficiency ratio of -0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-14.44 Billion ≈ $-9.78 Million USD) by net assets (₩265.17 Billion ≈ $179.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MEDIPOST Co. Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
MEDIPOST Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how MEDIPOST Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MEDIPOST Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEDIPOST Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xtract One Technologies Inc.
TO:XTRA
|
-0.220x |
|
Red Star Macalline Group Corporation Ltd
F:3S5
|
-0.008x |
|
Arctic Paper SA
WAR:ATC
|
0.015x |
|
HusCompagniet AS
CO:HUSCO
|
0.072x |
|
Viva Leisure Ltd
AU:VVA
|
0.366x |
|
Saga Pure ASA
OL:SAGA
|
0.177x |
|
Namsun Alumini
KO:008350
|
-0.021x |
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
0.030x |
Annual Cash Flow Conversion Efficiency for MEDIPOST Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of MEDIPOST Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see MEDIPOST Co. Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩252.60 Billion ≈ $171.18 Million |
₩-37.27 Billion ≈ $-25.25 Million |
-0.148x | -142.55% |
| 2023-12-31 | ₩313.66 Billion ≈ $212.56 Million |
₩-19.08 Billion ≈ $-12.93 Million |
-0.061x | -76.79% |
| 2022-12-31 | ₩179.97 Billion ≈ $121.96 Million |
₩-6.19 Billion ≈ $-4.20 Million |
-0.034x | -235.26% |
| 2021-12-31 | ₩159.48 Billion ≈ $108.08 Million |
₩4.06 Billion ≈ $2.75 Million |
0.025x | +66.11% |
| 2020-12-31 | ₩116.54 Billion ≈ $78.98 Million |
₩1.78 Billion ≈ $1.21 Million |
0.015x | -77.26% |
| 2019-12-31 | ₩111.59 Billion ≈ $75.62 Million |
₩7.51 Billion ≈ $5.09 Million |
0.067x | +23.88% |
| 2018-12-31 | ₩126.81 Billion ≈ $85.94 Million |
₩6.89 Billion ≈ $4.67 Million |
0.054x | +181.97% |
| 2017-12-31 | ₩104.45 Billion ≈ $70.78 Million |
₩-6.93 Billion ≈ $-4.69 Million |
-0.066x | +23.49% |
| 2016-12-31 | ₩143.31 Billion ≈ $97.12 Million |
₩-12.42 Billion ≈ $-8.42 Million |
-0.087x | -83.84% |
| 2015-12-31 | ₩146.48 Billion ≈ $99.27 Million |
₩-6.91 Billion ≈ $-4.68 Million |
-0.047x | -270.60% |
| 2014-12-31 | ₩117.34 Billion ≈ $79.52 Million |
₩-1.49 Billion ≈ $-1.01 Million |
-0.013x | -229.63% |
| 2011-12-31 | ₩115.04 Billion ≈ $77.96 Million |
₩1.13 Billion ≈ $765.03K |
0.010x | -- |
About MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more